News

This move aims to meet the funding needs of borrowers at different stages by introducing more flexible financing solutions. Bridge loans will primarily target real estate investors who require short-term capital turnover, while FHA loans, characterized by low down payments and relaxed credit requirements, will focus on serving first-time homebuyers and low- to middle-income groups. The coordinated launch of these two products is expected to further expand HeYi Bank's coverage in the housing credit market. This business expansion reflects HeYi Bank Holdings' intention to enhance its market competitiveness through a diversified credit strategy. Market analysis suggests that, in the current environment of interest rate fluctuations, the combination of bridge loans and government-backed loans may become a new path for small and medium-sized banks to improve asset returns.

According to the filing documents, the specific scale of this issuance has not yet been disclosed to the public.

According to CCTV, U.S. Customs: Tariffs ruled illegal by the Supreme Court will cease to be collected starting February 24. Federal Reserve Governor Waller: CEOs say artificial intelligence will lead to massive layoffs, and the March interest rate decision will depend on February labor data. According to Xinhua News Agency, Trump is reportedly considering a "small strike" followed by a "large strike" against Iran. According to CCTV, due to U.S. tariff risks, the European Union plans to suspend approval of the U.S.-EU trade agreement. Demand for U.S. stock market downside protection has reached a four-year high, and Goldman Sachs traders say professional investors are preparing for "some kind of breakout." After its stock price soared fourfold, SK Hynix pledged to continue expanding AI chip production capacity. In just 20 days, Moonshadow's revenue exceeded last year's total, making it the fastest domestic company to become a decacorn. Novo Nordisk's U.S. shares fell more than 15% pre-market, Eli Lilly rose more than 4% pre-market, and Novo Nordisk's CagriSema underperformed Eli Lilly's Zepbound in trials. Arcellx's U.S. shares rose nearly 78% pre-market, as Gilead Sciences will acquire Arcellx at $115 per share. Uncertainty over tariff policy looms over the market, with the U.S. dollar and U.S. stock futures falling, spot gold rising above $5,170, and oil prices declining. Japanese stock market closed for holiday.